| |
|
Product Name:
|
Nakayama
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Flaviviridae, Flavivirus
Species: Japanese encephalitis virus (JEV)
Strain/Isolate: Nakayama
Genotype: III
|
|
Additional Information:
|
JEV is an arbovirus transmitted in a zoonotic cycle among rice-field mosquitoes of the Culex species, with pigs as amplifying hosts and wading birds as intermediate hosts.3 It is the most important cause of epidemic encephalitis worldwide, with around 50,000 cases and 10,000 deaths per year affecting essentially children below 10 years of age.4 Approximately half the survivors have severe neurological disabilities. Most cases occur in rural areas of Southeast Asia, but the geographical area affected by JEV is expanding. In the absence of an effective antiviral treatment, prevention constitutes the best defense against this disease. Several vaccines are now available and others are under development.5,6,7,8,9
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from African green monkey kidney cells (Vero; ATCC® CCL-81™) infected with JEV, Nakayama.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-90 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: Vero cells (ATCC® CCL-81™)
Growth Medium: Minimum Essential Medium supplemented with 2% irradiated fetal bovine serum, or equivalent (lot-specific details are on the Certificate of Analysis)
Infection: Cells should be 80–90% confluent (not 100% confluent)
Incubation: 3 to 7 days at 37°C and 5% CO2
Cytopathic Effect: Cell rounding and sloughing
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Kasahara, S., et al. Kitasato Arch. Exp. Med. 13 (1936): 48, 248.
2. Rayner, J. O., et al. “Complete Genomic Sequence of Japanese Encephalitis Virus Strain Nakayama after One Passage in Vero Cells.” Direct submission, 23-APR?2007. GenBank: EF571853.
3. Solomon, T. “Control of Japanese Encephalitis--Within Our Grasp?” N. Engl. J. Med. 355 (2006): 869-871. PubMed: 16943399.
4. Diagana, M., P. M. Preux and M. Dumas. “Japanese Encephalitis Revisited.” J. Neurol. Sci. 262 (2007): 165- 170. PubMed: 17643451.
5. Yang, S. E., et al. “The Efficacy of Mouse-Brain Inactivated Nakayama Strain Japanese Encephalitis Vaccine--Results from 30 Years Experience in Taiwan.” Vaccine 24 (2006): 2669-2673. PubMed: 16314007.
6. Shlim, D. R. and T. Solomon. “Japanese Encephalitis Vaccine for Travelers: Exploring the Limits of Risk.” Clin. Infect. Dis. 35 (2002): 183-188. PubMed: 12087525.
7. Kurane, I. and T. Takasaki. “Immunogenicity and Protective Efficacy of the Current Inactivated Japanese Encephalitis Vaccine against Different Japanese Encephalitis Virus Strains.” Vaccine 18 (2000): 33-35. PubMed: 10821971.
8. Beasley, D. W., P. Lewthwaite and T. Solomon. “Current Use and Development of Vaccines for Japanese Encephalitis.” Expert Opin. Biol. Ther. 8 (2008): 95-106. PubMed: 18081539.
9. Solomon, T. “New Vaccines for Japanese Encephalitis.” Lancet Neurol. 7 (2008): 116-118. PubMed: 18207104.
10. Centers for Disease Control and Prevention. “Inactivated Japanese Encephalitis Virus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).” MMWR Recomm. Rep. 42 (1993): 1-15. PubMed: 8381504.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Japanese Encephalitis Virus, Nakayama, NR-90."
|
|
Biosafety Level:
|
3
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|